Molecular dynamics study of differential effects of serotonin-2A-receptor (5-HT2AR) modulators.

The serotonin-2A receptor (5-HT2AR) is a target for antidepressants that could work quickly or in treatment-resistant cases, but activating it can cause hallucinations. Recent research suggests certain partial agonists might produce antidepressant effects without hallucinations, though the molecular details are unclear. This study used molecular dynamics simulations of the receptor bound to two antipsychotics, three potential non-hallucinogens, and two hallucinogens. Findings suggest modest receptor activation yields only antidepressant effects, while hallucinations result from excessive activation. Modest activation via a sufficiently weak partial agonist may offer a viable drug development pathway, whereas microdosing may be problematic due to abuse potential and narrow therapeutic windows.

Study at a glance

Abstract

The serotonin-2A receptor (5-HT2AR) is an interesting target for drug design in the context of antidepressants that might have a rapid onset of action and/or be effective in treatment-resistant cases. The main challenge, however, is that the activation of this receptor can provoke hallucinations. Recent studies have shown that activating the receptor with certain (partial) agonists could potentially give rise to antidepressant effect without hallucinogenic side effects. Although substantial research has been done in this area, the atomistic details of this differential activation of the serotonin-2A receptor are not fully understood. In the present study we performed multiple atomistic molecular dynamics (MD) simulations on 5-HT2AR bound with two antipsychotics, three different potential non-hallucinogens and two hallucinogens to identify the receptor's ligand dependent conformations. Overall, our findings suggest that modest 5-HT2AR activation would only yield antidepressant effects and hallucinations result from excessive activation. While modest activation through microdosing may be problematic on account of abuse potential as well as possibly narrow and patient-dependent therapeutic windows, modest activation through administration of a sufficiently weak partial agonist may offer a viable drug development pathway.